Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) reported 2025 results and a corporate update on March 10, 2026. Key highlights include $45.1M cash at year-end and subsequent ~$25.0M private placement, implying $70.1M aggregate resources expected to fund operations into H1 2028.

Clinical progress: positive early safety and efficacy signals from OPGx-BEST1 (12-letter BCVA gain; 23% CST reduction), Phentolamine sNDA accepted with PDUFA date Oct 17, 2026, LYNX-3 topline H1 2026, OPGx-LCA5 pivotal dosing expected H2 2026, and funding secured for OPGx-MERTK development.

Positive

• Cash resources of $70.1M (post-placement) expected to fund into H1 2028
• OPGx-BEST1 sentinel patient showed 12-letter BCVA gain and 23% CST reduction
• sNDA accepted for Phentolamine with PDUFA date Oct 17, 2026
• Funding secured for OPGx-MERTK clinical trial from Abu Dhabi healthcare fund
• License and collaboration revenue increased to $14.2M in 2025 (from $11.0M)

Negative

• Net loss of $49.6M in 2025, reflecting continued operating cash burn
• R&D expenses rose to $30.8M (+14% vs 2024) and G&A to $22.0M (+21% vs 2024)
• Aggregate cash runway only into H1 2028, indicating need for additional financing thereafter
• Fair value increase of warrant and derivative liabilities contributed an $11.5M headwind

News Market Reaction – IRD

+1.68%

19 alerts

+1.68% Session close to close

+5.8% Peak in 30 min

$365.51M Market Cap

0.4x Rel. Volume

In the Mar 10 session, IRD gained 1.68%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.8% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement combines positive BEST1 and LCA5 clinical signals, advancement of additional IRD g...

Analysis

This announcement combines positive BEST1 and LCA5 clinical signals, advancement of additional IRD gene therapy programs, and confirmation of a $70.1M cash position funding operations into the first half of 2028. Revenue from collaborations grew to $14.2M, while R&D and G&A expenses also increased. Investors may focus on how efficiently Opus converts this expanded runway into pivotal data, regulatory outcomes, and partnership value while managing net losses and development risk across a broad pipeline.

Key Figures

Cash & equivalents: $45.1M Private placement: $25.0M Aggregate cash: $70.1M +5 more

8 metrics

Cash & equivalents $45.1M As of Dec 31, 2025

Private placement $25.0M Gross proceeds raised post-Q4 2025

Aggregate cash $70.1M Pro forma funding operations into H1 2028

2025 revenue $14.2M License and collaboration revenue vs $11.0M in 2024

R&D expenses 2025 $30.8M Up from $26.9M in 2024

G&A expenses 2025 $22.0M Up from $18.2M in 2024

Net loss 2025 $49.6M ($0.80/share) Improved from $57.5M ($2.15/share) in 2024

BCVA gain 12 letters Sentinel BEST1 participant at 3 months

Previous Earnings Reports

5 past events · Latest: Nov 12 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 12	Q3 2025 earnings	Positive	-2.5%	Q3 2025 results plus positive LCA5 data and RMAT meeting details.
Aug 13	Q2 2025 earnings	Positive	+7.3%	Q2 2025 results with RMAT, strong LCA5 data and Phentolamine milestones.
May 15	Q1 2025 earnings	Positive	+0.0%	Q1 2025 update with LCA5 data, BEST1 progress and strengthened cash.
Mar 31	Full year 2024	Negative	-2.8%	2024 results showing revenue decline and larger net loss post-acquisition.
Nov 12	Q3 2024 earnings	Negative	-2.6%	Q3 2024 results with lower revenue and a swing to net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings and corporate updates have typically led to modest stock moves, with negative reactions more common when financial metrics soften despite positive pipeline progress.

Recent Company History

Recent earnings updates for Opus Genetics have combined advancing gene therapy programs and the Phentolamine franchise with evolving cash runway disclosures. Prior reports highlighted RMAT designation for OPGx-LCA5, positive Phase 1/2 data, and cash positions ranging from $30.3M to over $50M, generally funding operations into 2026–2027. Market reactions have often been small and sometimes negative even when clinical news was favorable, suggesting investors scrutinize dilution, losses, and revenue trends around these updates.

Key Terms

rare pediatric disease priority review voucher, pdufa, phase 1/2, phase 3, +4 more

8 terms

rare pediatric disease priority review voucher regulatory

"Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity..."

A rare pediatric disease priority review voucher is a transferable regulatory benefit awarded to a company that wins approval for a drug treating a serious but uncommon childhood illness. It works like a “fast-pass” with regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs.

pdufa regulatory

"FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine..."

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

phase 1/2 medical

"two participants treated to date in the Phase 1/2 trial (BIRD-1)..."

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

phase 3 medical

"pivotal Phase 3 trial, which is targeted to enroll as few as eight participants..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

best corrected visual acuity (bcva) medical

"including an equivalent 12-letter gain in Best Corrected Visual Acuity (BCVA)..."

Best corrected visual acuity (BCVA) measures how clearly a person can see when wearing their optimal glasses or contact lenses, typically tested by reading letters on an eye chart. Investors care because BCVA is a common clinical-trial endpoint and regulatory benchmark for eye treatments and devices—improvements indicate real patient benefit and can drive product approval, market adoption, and revenue potential, much like a performance score that validates a new tool.

central subfield thickness (cst) medical

"Structural improvement in central subfield thickness (CST) was observed with a 23% decrease..."

Central subfield thickness (CST) is the average thickness of the central portion of the retina, measured by an imaging scan called optical coherence tomography; think of it as the depth of the retina at the macula, the eye’s sharp-vision center. Investors care because changes in CST are a common, measurable sign that an eye treatment is working or failing — like a thermometer for swelling or healing — and those changes often influence regulatory decisions, trial outcomes and market value for therapies targeting retinal disease.

supplemental new drug application (snda) regulatory

"The FDA accepted the Company’s supplemental New Drug Application (sNDA) for Phentolamine..."

A supplemental new drug application (snda) is a formal request made to regulatory authorities to make changes to an already approved medication, such as adding new uses, adjusting dosages, or improving manufacturing processes. It’s similar to updating a product’s packaging or instructions after it has been approved for sale. For investors, an snda signals ongoing development or improvements that could impact a company’s future sales or regulatory approval prospects.

presbyopia medical

"Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia..."

Presbyopia is the gradual loss of the eye’s ability to focus on close objects as the lens stiffens with age, causing tasks like reading or using a phone to require holding things farther away or using glasses. It matters to investors because it drives steady demand for corrective products and treatments—such as reading glasses, contact lenses, surgical procedures and emerging drugs—much like an aging population consistently needs new or replacement consumer goods and services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -

- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -

- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -

- Funding from prominent healthcare investors expected to extend cash runway into 2028 -

RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the year ended December 31, 2025, and provided a corporate update.

“We are delivering a steady cadence of data and milestones across our pipeline,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “With positive clinical results from both our BEST1 and LCA5 gene therapy programs, new funding for our MERTK program and an upcoming FDA PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, we are advancing therapies with both scientific promise and compelling commercial potential. The reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program further strengthens our work, reinforcing long‑term incentives that support sustainable investment in rare gene therapy development. With multiple catalysts ahead and a capital‑efficient operating model, we believe Opus is positioned to create significant long‑term value for shareholders.”

Pipeline Updates

OPGx-BEST1 – Gene Therapy for BEST1-Related IRD

• Recruitment is ongoing at multiple U.S. sites with two participants treated to date in the Phase 1/2 trial (BIRD-1) that includes patients with both dominant and recessive forms of BEST disease.
• Positive initial three-month data from the first (sentinel) participant presented at Macula Society
  • The data demonstrated that OPGx-BEST1 was well tolerated with no ocular inflammation, no ocular or treatment-related adverse events, and no dose limiting toxicities observed to date.
  • Early signals of functional vision improvement were observed, including an equivalent 12-letter gain in Best Corrected Visual Acuity (BCVA) in the treated study eye.
  • Structural improvement in central subfield thickness (CST) was observed with a 23% decrease in the study eye.
  • Resolution of intraretinal fluid was also seen as early as 1-month in areas with less atrophy.
• Three-month results from the full Cohort 1 are expected in mid-year 2026.
  
  

OPGx-LCA5 – Gene Therapy for Leber Congenital Amaurosis (LCA5)

• Recruitment ongoing with multiple participants enrolled to date in a run-in period for the pivotal Phase 3 trial, which is targeted to enroll as few as eight participants in a single arm, 12-month study utilizing an adaptive design. Dosing with OPGx-LCA5 expected in the second half of 2026.
• Application expected to be submitted in Q1 2026 for Rare Disease Evidence Principles (RDEP) review process from the U.S. Food and Drug Administration (FDA), designed to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
• Presentation of Phase 1/2 six-month pediatric cohort data expected at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) conference in May 2026.
  
  

Preclinical Gene Therapy Pipeline

• Funding secured from Abu Dhabi’s Healthcare Research and Innovation Fund to conduct a clinical trial evaluating OPGx-MERTK for MERTK-related retinitis pigmentosa (RP), a rare IRD that causes progressive vision loss and eventual blindness. Clinical development activities are underway.
• Preclinical work ongoing for Opus’ broad IRD pipeline related to genetic mutations in RHO, CNGB1, RDH12-LCA, and NMNAT1, with one to two programs targeted to enter clinical testing this year.
  
  

Phentolamine Ophthalmic Solution 0.75% (PS)

• The FDA accepted the Company’s supplemental New Drug Application (sNDA) for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia and set a PDUFA action date of October 17, 2026.
• LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions (dim light disturbances), is ongoing with topline results expected in the first half of 2026.
  
  

Recent Medical Publications and Presentations

• Presentation at The Macula Society Annual Meeting titled “Preliminary Results from Sentinel Patient in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations.”
• Presentation at the Asia-Pacific Academy of Ophthalmology Congress (APAO) titled “Gene Therapy for BEST1 Inherited Retinal Disease.”
• Presentation at the Advanced Therapies Week Conference titled “Building Scalable Viral Vector Manufacturing Models.”
• Presentation at the Cell and Gene Meeting on the Mesa titled “Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases.”
• Poster presentation at the American Academy of Optometry Annual Meeting 2025 titled “LYNX-2: A Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution in Post-Keratorefractive Surgery Subjects with Decreased Mesopic Visual Acuity.”
• Presentation at Eyecelerator at the American Academy of Ophthalmology (AAO) Annual Meeting titled “Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases.”
  
  

Financial Results for the Year Ended December 31, 2025

Cash Position: As of December 31, 2025, Opus Genetics had cash and cash equivalents of $45.1 million. Subsequent to the end of the fourth quarter, the Company raised approximately $25.0 million in gross proceeds through a private placement of equity securities. Based on current operating plans, the Company believes its aggregate cash resources of $70.1 million will fund operations into the first half of 2028, excluding any potential proceeds from callable warrants or future milestone payments. 

Revenue: License and collaborations revenue totaled $14.2 million for the year ended December 31, 2025, compared to $11.0 million for the same period in 2024. Revenue in both periods was driven by the Company’s collaboration with Viatris, Inc. from reimbursement of research and development (R&D) services.

Research and Development (R&D) Expenses: R&D expenses were $30.8 million for the year ended December 31, 2025, compared to $26.9 million for the same period in 2024. The increase was primarily attributable to higher costs related to clinical research, toxicology, payroll, professional services and other operating expenses, partially offset by lower manufacturing and regulatory costs. R&D expenses included $1.0 million in stock-based compensation expense during each of the years ended December 31, 2025 and 2024.

General and Administrative (G&A) Expenses: G&A expenses were $22.0 million for the year ended December 31, 2025, compared to $18.2 million for the same period in 2024. The increase was primarily attributable to higher legal and patent-related costs, payroll and public company-related costs, and professional service fees. G&A expenses included $2.4 million in stock-based compensation expense during each of the years ended December 31, 2025 and 2024.

Net Loss: Net loss for the year ended December 31, 2025 was $49.6 million, or ($0.80) per basic and diluted share, compared to a net loss of $57.5 million, or ($2.15) per basic and diluted share, for the same period in 2024. The year‑over‑year decrease in net loss was primarily driven by the absence of the $28.0 million acquired in‑process research and development charge recognized in 2024, partially offset by an $11.5 million increase in the fair value of warrant and other derivative liabilities associated with the Company’s March 2025 financings and increases to R&D and G&A expense as noted above.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%, beyond its approved use for pharmacologically induced mydriasis, with a supplemental new drug application under review for presbyopia and an ongoing Phase 3 pivotal trial for mesopic, low contrast conditions after keratorefractive surgery (dim light disturbances). The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway, the clinical development, clinical results, preclinical data and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12 and earlier stage programs, and expectations regarding us, our business prospects and our results of operations, and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

-Financial Tables Follow-

Opus Genetics, Inc. Consolidated Balance Sheets (in thousands, except share amounts and par value)
		As of December 31,
		2025				2024
Assets
Current assets:
Cash and cash equivalents		$	45,091			$	30,321
Accounts receivable			1,995				3,563
Contract assets and unbilled receivables (Note 10)			1,170				2,209
Prepaids and other current assets			1,788				515
Short-term investments			—				2
Total current assets			50,044				36,610
Property and equipment, net			199				252
Total assets		$	50,243			$	36,862
Liabilities, Series A preferred stock and stockholders’ equity
Current liabilities:
Accounts payable		$	3,293			$	3,148
Accrued expenses and other liabilities			4,488				8,147
Total current liabilities			7,781				11,295
Warrant liabilities			25,985				—
Funding agreement, related party			1,129				—
Total liabilities			34,895				11,295
Commitments and contingencies (Note 3 and Note 9)
Series A preferred stock, par value $0.0001; no shares and 14,146 shares were designated as of December 31, 2025 and 2024, respectively; no shares and 14,145.374 shares issued and outstanding at December 31, 2025 and 2024, respectively.			—				18,843
Stockholders’ equity:
Preferred stock, par value $0.0001; 10,000,000 and 9,985,854 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024.			—				—
Common stock, par value $0.0001; 125,000,000 authorized as of December 31, 2025 and 2024; 69,894,507 and 31,574,657 shares issued and outstanding at December 31, 2025 and 2024, respectively.			7				3
Additional paid-in capital			203,930				145,719
Accumulated deficit			(188,589	)			(138,998	)
Total stockholders’ equity			15,348				6,724
Total liabilities, Series A preferred stock, and stockholders’ equity		$	50,243			$	36,862

Opus Genetics, Inc. Consolidated Statements of Comprehensive Loss (in thousands, except share and per share amounts)
		For the Year Ended December 31,
		2025				2024
License and collaborations revenue		$	14,196			$	10,992
Operating expenses:
Research and development			30,812				26,851
General and administrative			21,983				18,215
Acquired in-process research and development			—				28,000
Total operating expenses			52,795				73,066
Loss from operations			(38,599	)			(62,074	)
Fair value change in warrant and other derivative liabilities			(11,515	)			72
Financing costs			(1,337	)			—
Interest expense			(129	)			—
Other income, net			1,989				4,470
Loss before income taxes			(49,591	)			(57,532	)
Provision for income taxes			—				—
Net loss			(49,591	)			(57,532	)
Other comprehensive loss, net of tax			—				—
Comprehensive loss		$	(49,591	)		$	(57,532	)
Net loss per share
Basic and diluted		$	(0.80	)		$	(2.15	)
Number of shares used in per share calculations:
Basic and diluted			62,221,901				26,715,526

Source: Opus Genetics, Inc.

FAQ

How long will Opus Genetics (IRD) cash support operations after the March 2026 financing?

Opus expects its aggregate cash resources of $70.1M to fund operations into the first half of 2028. According to the company, this excludes potential proceeds from callable warrants or future milestone payments and assumes current operating plans.

What is the PDUFA date for Opus Genetics' Phentolamine Ophthalmic Solution (IRD)?

The FDA set a PDUFA action date of October 17, 2026 for Phentolamine 0.75%. According to the company, this follows acceptance of its supplemental NDA and aligns with ongoing LYNX-3 Phase 3 data readouts expected H1 2026.

What were the early clinical results reported for Opus' OPGx-BEST1 gene therapy (IRD)?

Early three-month data showed the sentinel patient was well tolerated and had a 12-letter BCVA improvement and 23% CST reduction. According to the company, no ocular inflammation or dose-limiting toxicities were observed through three months.

When does Opus plan to dose patients in the OPGx-LCA5 pivotal study (IRD)?

Opus expects dosing with OPGx-LCA5 in the second half of 2026 for its pivotal single-arm, 12-month adaptive Phase 3. According to the company, an RDEP submission was targeted for Q1 2026 to support review for rare disease programs.

What funding did Opus secure for its MERTK program and what does it enable (IRD)?

Opus secured funding from Abu Dhabi’s Healthcare Research and Innovation Fund to run a clinical trial of OPGx-MERTK. According to the company, this financing supports clinical development activities now underway for MERTK-related retinitis pigmentosa.

How did Opus Genetics' 2025 revenue and net loss compare to 2024 (IRD)?

2025 license and collaboration revenue rose to $14.2M from $11.0M in 2024, while net loss improved to $49.6M from $57.5M. According to the company, the net loss decrease reflected absence of a prior acquired IPRD charge partially offset by other items.